ENTX · Why this verdict
Why Entera Bio (ENTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Entera Bio is a pre-revenue biotech dependent on its EB613 program, with quarterly losses of about 0.06 to 0.14 per share and an uptrend pullback on strong volume, but quality sits below the engine's floor.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Pipeline value is concentrated in EB613, a high-severity concentration risk for a biotech with no product revenue. Bear case | EB613 advances through its next clinical milestone within 12 months. | ↓Deteriorating |
| CounterA single successful program can justify the valuation, and the stock has strong implied volatility of 231% pricing that possibility. | ||
The company is cash-burning with negative free cash flow and no competitive moat, giving a quality score of 1.6 against the 4.0 floor. Quality breakdown | Quarterly EPS loss stays at or below 0.10 per share. | →Stable |
| CounterLosses of 0.06 to 0.14 per share a quarter are small, and current ratio scores 5 on liquidity. | ||
The shares are in an uptrend pullback at RSI 36, above the 200-day average, with a volume surge of 2.9x on an up move. Momentum breakdown | The price holds above the 200-day average while volume stays elevated. | ↓Deteriorating |
| CounterOn-balance volume is still falling, and the momentum reading of 6.0 may not persist. | ||
The latest quarter lost 0.14 per share against an estimate of 0.08, a miss of 75%, after several in-line or better quarters. Earnings | Quarterly results return to within 10% of estimates. | →Stable |
| CounterEight of the last twelve reports met or beat estimates, so one miss may be timing rather than a trend. | ||
Pipeline value is concentrated in EB613, a high-severity concentration risk for a biotech with no product revenue.
↓DeterioratingBear case
- Expectation
- EB613 advances through its next clinical milestone within 12 months.
CounterA single successful program can justify the valuation, and the stock has strong implied volatility of 231% pricing that possibility.
The company is cash-burning with negative free cash flow and no competitive moat, giving a quality score of 1.6 against the 4.0 floor.
→StableQuality breakdown
- Expectation
- Quarterly EPS loss stays at or below 0.10 per share.
CounterLosses of 0.06 to 0.14 per share a quarter are small, and current ratio scores 5 on liquidity.
The shares are in an uptrend pullback at RSI 36, above the 200-day average, with a volume surge of 2.9x on an up move.
↓DeterioratingMomentum breakdown
- Expectation
- The price holds above the 200-day average while volume stays elevated.
CounterOn-balance volume is still falling, and the momentum reading of 6.0 may not persist.
The latest quarter lost 0.14 per share against an estimate of 0.08, a miss of 75%, after several in-line or better quarters.
→StableEarnings
- Expectation
- Quarterly results return to within 10% of estimates.
CounterEight of the last twelve reports met or beat estimates, so one miss may be timing rather than a trend.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.4 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 215%
Insider
5.0/10data confidence 50%Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 2.0 |
| 52w position | 4.8 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.3 |
| days to cover | 1.1 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 5.4 |
| debt equity | 9.8 |
- ▸High IV: 115%
- ▸Above max pain $2
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 1.6 |
| news activity | 5.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (4)
- INSIDER:OK
- EARNINGS_PROXIMITY:15d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.5<4.5
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupMomentum Cont — Trend continuation, RSI 70, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.5<4.5 outcome against Sentiment at 6.8 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 6.8, Value at 5.0, and Growth at 5.0; the weakest are Quality at 1.6, Technical at 2.7, and Peer rank at 3.8. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Program Concentration
Trip ifNumber of clinical-stage programs rises to at least 2 from the current 1.
- P2Cash Burning Pre Revenue
Trip ifQuality score rises above 4.0 from the current 1.6.
- P3Uptrend Pullback Volume
Trip ifShare price falls below the 200-day moving average for at least 10 consecutive sessions.
- P4Widening Loss Latest Quarter
Trip ifEPS beats estimates in at least 2 consecutive quarters.